Search
947 results for “bisonte”
-
Die BioNTech-Gründer sind im zweiten Corona-Jahr Favoriten beim Deutschen Zukunftspreis. Können sie gegen Teams mit quantenzählenden Computertomographen oder Pneus aus Löwenzahn bestehen?
Deutscher Zukunftspreis: Quanten-CT, Reifen aus Löwenzahn und Corona-Impfstoff im Rennen | DW | 16.11.2021
#DeutscherZukunftspreis #BioNTech #Continental #Siemens #Computertomograph #Reifen #Pneus #Löwenzahn #Quanten -
For BioNTech, the COVID-19 vaccine was simply the opening act - BioNTech’s founding story dates back to the late 1990s, when CEO and co-founder Uğ... - http://feedproxy.google.com/~r/Techcrunch/~3/RgZuyRi_080/ #techcrunchdisrupt2021health #techcrunchdisrupt2021 #techcrunchdisrupt #ecdigitalbiotech #ugursahin #startups #biontech #mayfield #biotech #health #tc
-
[...]
Wie Müll würde #Biontech die Arbeitsplätze entsorgen, kritisiert der ehemalige #Curevac-Chef die Konzernentscheidung. So funktioniert #Kapitalismus pur: #Profite und Rentabilität entscheiden darüber, wo es hingeht. Da gibt es kein Mitspracherecht für Betriebsräte und keine #Verantwortung des Unternehmens für die Folgen.
[...]
-
"Unsere größte Stärke": Biontech kehrt zu seinen "Wurzeln" zurück - Betriebsrat verärgert https://www.n-tv.de/wirtschaft/Biontech-kehrt-zu-seinen-Wurzeln-zurueck-Betriebsrat-veraergert-id30826057.html?utm_source=mastodon&utm_medium=dlvr.it&utm_content=n-tv.de%20-%20Startseite&utm_term=%40ntv%40mstdn.social
-
Kritik am BioNTech-Rückzug aus Deutschland
Nach der verkündeten Schließung der Produktionsstätten von BioNTech in Deutschland wird vor möglichen Engpässen gewarnt. Scharfe Kritik kommt auch vom CureVac-Gründer und der Gewerkschaft.
-
Avis aux bisontin-es (ou pas loin) : festival La Cisalle les 16-17 mai (🤩). Pour apprendre à faire de la restauration en menuiserie, de la construction d'auvent, de la grimpe d'arbre, de la lecture de carte IGN, de la technique corde, de la couture, du ponçage, de la mécanique vélo, de la remorque... https://framaforms.org/la-cisaille-2-1764516310
#besancon #doubs -
Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too low to generate the needed data. https://www.japantimes.co.jp/business/2026/04/02/companies/pfizer-biontech-covid-vaccine/?utm_medium=Social&utm_source=mastodon #business #companies #pfizer #biontech #uscovid19 #vaccines
-
Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too low to generate the needed data. https://www.japantimes.co.jp/business/2026/04/02/companies/pfizer-biontech-covid-vaccine/?utm_medium=Social&utm_source=mastodon #business #companies #pfizer #biontech #uscovid19 #vaccines
-
Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too low to generate the needed data. https://www.japantimes.co.jp/business/2026/04/02/companies/pfizer-biontech-covid-vaccine/?utm_medium=Social&utm_source=mastodon #business #companies #pfizer #biontech #uscovid19 #vaccines
-
Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too low to generate the needed data. https://www.japantimes.co.jp/business/2026/04/02/companies/pfizer-biontech-covid-vaccine/?utm_medium=Social&utm_source=mastodon #business #companies #pfizer #biontech #uscovid19 #vaccines
-
At both Moderna and BioNTech, the complex logistics of conducting the dozens of different quality-control tests required for each production run falls to algorithms powered by AI.
Before being approved for release, doses of SpikeVax underwent 40 distinct tests that tracked the chemistry, biochemistry, microbiology and sterility of every vial.
With COVID vaccines, the sterility test alone,
which ensures that vials are not contaminated with organisms,
took two weeks.Refinements have since compressed that test to eight days, Nickerson says.
Ultimately the goal is to shrink it to five days and complete the other tests within that same window.
“The reason it’s hard is we have to design the equipment,”
he explains.“None of this stuff’s off-the-shelf.”
At the same time, the background science is,
at least in theory,
easily adapted from work that’s already been done.Lennard Lee,
an adviser to the U.K.’s National Health Service overseeing the rollout of clinical trials for cancer vaccines,
says the pandemic gave regulators there a running start on trials for mRNA cancer vaccines.In partnership with BioNTech, the NHS launched a program that aims to provide personalized vaccines to up to 10,000 cancer patients in the next five years.
And the NHS and Moderna have invested in a facility that could produce up to 250 million vaccines per year.
In that interval,
as manufacturers work to reduce production times and costs,
clinical trials will evaluate alternative dosage and delivery mechanisms, Lee says.Although current protocol is for vaccines to target #micrometastases
—small groups of cancer cells that spread to other parts of the body
and linger after cancerous tumors are removed surgically
—there’s no shortage of adjustments that might follow from more data
or improved screening.Could one deliver a therapeutic vaccine to tackle a tumor before it is large enough to operate on?
Or maybe one could even administer a prophylactic shot that prevents tumor formation in the first place?
With a unified health system and world-class research and manufacturing facilities, Lee says,
the U.K. is well positioned to advance research that would answer such questions.Fully realizing the potential of personalized mRNA vaccines for cancer, however,
will require more trials in the U.S.,
which has many more cancer research centers than the U.K.⚠️But the ability of the U.S. to lead this effort is now in jeopardy.
The federal government has long been the dominant source of funding for cancer research in the U.S.
Miriam Merad, a cancer immunologist at the Icahn School of Medicine at Mount Sinai in New York City, says that
in a typical year, funding from the NIH accounts for more than half of the research budget at her institution.In President Donald Trump’s first term, threatened cuts to the NIH never quite materialized.
Society is not going to let that happen,
Merad thought.🆘 But just weeks into Trump’s second term, the NIH announced plans to limit indirect contributions to research grants to 15 percent,
-- meaning that for every $100 in funding awarded, only $15 extra would be included for overhead
—a dramatic departure from historical rates in the range of 50 to 60 percent.“This is an operation,” Merad says,
gesturing to the building where she works,
which is dotted with six-figure pieces of equipment
and has an entire floor dedicated to rearing mice used in research.“We have to pay salaries;
we have to buy food for the animals.
We have to pay service contracts because we have instruments that need to be serviced all the time.”These are not expenses that can be easily paused or restarted
based on the fate of a single grant.Within just a few months of the NIH announcement,
Merad’s department had reduced hires of new postdocs,
and Mount Sinai’s medical school had to shrink the size of its incoming class.#neoantigens #driver #antigens #passenger #mutations #neoantigens #checkpointinhibitors #WilliamColey #immunotherapy #stroma #MHC
-
At both Moderna and BioNTech, the complex logistics of conducting the dozens of different quality-control tests required for each production run falls to algorithms powered by AI.
Before being approved for release, doses of SpikeVax underwent 40 distinct tests that tracked the chemistry, biochemistry, microbiology and sterility of every vial.
With COVID vaccines, the sterility test alone,
which ensures that vials are not contaminated with organisms,
took two weeks.Refinements have since compressed that test to eight days, Nickerson says.
Ultimately the goal is to shrink it to five days and complete the other tests within that same window.
“The reason it’s hard is we have to design the equipment,”
he explains.“None of this stuff’s off-the-shelf.”
At the same time, the background science is,
at least in theory,
easily adapted from work that’s already been done.Lennard Lee,
an adviser to the U.K.’s National Health Service overseeing the rollout of clinical trials for cancer vaccines,
says the pandemic gave regulators there a running start on trials for mRNA cancer vaccines.In partnership with BioNTech, the NHS launched a program that aims to provide personalized vaccines to up to 10,000 cancer patients in the next five years.
And the NHS and Moderna have invested in a facility that could produce up to 250 million vaccines per year.
In that interval,
as manufacturers work to reduce production times and costs,
clinical trials will evaluate alternative dosage and delivery mechanisms, Lee says.Although current protocol is for vaccines to target #micrometastases
—small groups of cancer cells that spread to other parts of the body
and linger after cancerous tumors are removed surgically
—there’s no shortage of adjustments that might follow from more data
or improved screening.Could one deliver a therapeutic vaccine to tackle a tumor before it is large enough to operate on?
Or maybe one could even administer a prophylactic shot that prevents tumor formation in the first place?
With a unified health system and world-class research and manufacturing facilities, Lee says,
the U.K. is well positioned to advance research that would answer such questions.Fully realizing the potential of personalized mRNA vaccines for cancer, however,
will require more trials in the U.S.,
which has many more cancer research centers than the U.K.⚠️But the ability of the U.S. to lead this effort is now in jeopardy.
The federal government has long been the dominant source of funding for cancer research in the U.S.
Miriam Merad, a cancer immunologist at the Icahn School of Medicine at Mount Sinai in New York City, says that
in a typical year, funding from the NIH accounts for more than half of the research budget at her institution.In President Donald Trump’s first term, threatened cuts to the NIH never quite materialized.
Society is not going to let that happen,
Merad thought.🆘 But just weeks into Trump’s second term, the NIH announced plans to limit indirect contributions to research grants to 15 percent,
-- meaning that for every $100 in funding awarded, only $15 extra would be included for overhead
—a dramatic departure from historical rates in the range of 50 to 60 percent.“This is an operation,” Merad says,
gesturing to the building where she works,
which is dotted with six-figure pieces of equipment
and has an entire floor dedicated to rearing mice used in research.“We have to pay salaries;
we have to buy food for the animals.
We have to pay service contracts because we have instruments that need to be serviced all the time.”These are not expenses that can be easily paused or restarted
based on the fate of a single grant.Within just a few months of the NIH announcement,
Merad’s department had reduced hires of new postdocs,
and Mount Sinai’s medical school had to shrink the size of its incoming class.#neoantigens #driver #antigens #passenger #mutations #neoantigens #checkpointinhibitors #WilliamColey #immunotherapy #stroma #MHC
-
At both Moderna and BioNTech, the complex logistics of conducting the dozens of different quality-control tests required for each production run falls to algorithms powered by AI.
Before being approved for release, doses of SpikeVax underwent 40 distinct tests that tracked the chemistry, biochemistry, microbiology and sterility of every vial.
With COVID vaccines, the sterility test alone,
which ensures that vials are not contaminated with organisms,
took two weeks.Refinements have since compressed that test to eight days, Nickerson says.
Ultimately the goal is to shrink it to five days and complete the other tests within that same window.
“The reason it’s hard is we have to design the equipment,”
he explains.“None of this stuff’s off-the-shelf.”
At the same time, the background science is,
at least in theory,
easily adapted from work that’s already been done.Lennard Lee,
an adviser to the U.K.’s National Health Service overseeing the rollout of clinical trials for cancer vaccines,
says the pandemic gave regulators there a running start on trials for mRNA cancer vaccines.In partnership with BioNTech, the NHS launched a program that aims to provide personalized vaccines to up to 10,000 cancer patients in the next five years.
And the NHS and Moderna have invested in a facility that could produce up to 250 million vaccines per year.
In that interval,
as manufacturers work to reduce production times and costs,
clinical trials will evaluate alternative dosage and delivery mechanisms, Lee says.Although current protocol is for vaccines to target #micrometastases
—small groups of cancer cells that spread to other parts of the body
and linger after cancerous tumors are removed surgically
—there’s no shortage of adjustments that might follow from more data
or improved screening.Could one deliver a therapeutic vaccine to tackle a tumor before it is large enough to operate on?
Or maybe one could even administer a prophylactic shot that prevents tumor formation in the first place?
With a unified health system and world-class research and manufacturing facilities, Lee says,
the U.K. is well positioned to advance research that would answer such questions.Fully realizing the potential of personalized mRNA vaccines for cancer, however,
will require more trials in the U.S.,
which has many more cancer research centers than the U.K.⚠️But the ability of the U.S. to lead this effort is now in jeopardy.
The federal government has long been the dominant source of funding for cancer research in the U.S.
Miriam Merad, a cancer immunologist at the Icahn School of Medicine at Mount Sinai in New York City, says that
in a typical year, funding from the NIH accounts for more than half of the research budget at her institution.In President Donald Trump’s first term, threatened cuts to the NIH never quite materialized.
Society is not going to let that happen,
Merad thought.🆘 But just weeks into Trump’s second term, the NIH announced plans to limit indirect contributions to research grants to 15 percent,
-- meaning that for every $100 in funding awarded, only $15 extra would be included for overhead
—a dramatic departure from historical rates in the range of 50 to 60 percent.“This is an operation,” Merad says,
gesturing to the building where she works,
which is dotted with six-figure pieces of equipment
and has an entire floor dedicated to rearing mice used in research.“We have to pay salaries;
we have to buy food for the animals.
We have to pay service contracts because we have instruments that need to be serviced all the time.”These are not expenses that can be easily paused or restarted
based on the fate of a single grant.Within just a few months of the NIH announcement,
Merad’s department had reduced hires of new postdocs,
and Mount Sinai’s medical school had to shrink the size of its incoming class.#neoantigens #driver #antigens #passenger #mutations #neoantigens #checkpointinhibitors #WilliamColey #immunotherapy #stroma #MHC
-
At both Moderna and BioNTech, the complex logistics of conducting the dozens of different quality-control tests required for each production run falls to algorithms powered by AI.
Before being approved for release, doses of SpikeVax underwent 40 distinct tests that tracked the chemistry, biochemistry, microbiology and sterility of every vial.
With COVID vaccines, the sterility test alone,
which ensures that vials are not contaminated with organisms,
took two weeks.Refinements have since compressed that test to eight days, Nickerson says.
Ultimately the goal is to shrink it to five days and complete the other tests within that same window.
“The reason it’s hard is we have to design the equipment,”
he explains.“None of this stuff’s off-the-shelf.”
At the same time, the background science is,
at least in theory,
easily adapted from work that’s already been done.Lennard Lee,
an adviser to the U.K.’s National Health Service overseeing the rollout of clinical trials for cancer vaccines,
says the pandemic gave regulators there a running start on trials for mRNA cancer vaccines.In partnership with BioNTech, the NHS launched a program that aims to provide personalized vaccines to up to 10,000 cancer patients in the next five years.
And the NHS and Moderna have invested in a facility that could produce up to 250 million vaccines per year.
In that interval,
as manufacturers work to reduce production times and costs,
clinical trials will evaluate alternative dosage and delivery mechanisms, Lee says.Although current protocol is for vaccines to target #micrometastases
—small groups of cancer cells that spread to other parts of the body
and linger after cancerous tumors are removed surgically
—there’s no shortage of adjustments that might follow from more data
or improved screening.Could one deliver a therapeutic vaccine to tackle a tumor before it is large enough to operate on?
Or maybe one could even administer a prophylactic shot that prevents tumor formation in the first place?
With a unified health system and world-class research and manufacturing facilities, Lee says,
the U.K. is well positioned to advance research that would answer such questions.Fully realizing the potential of personalized mRNA vaccines for cancer, however,
will require more trials in the U.S.,
which has many more cancer research centers than the U.K.⚠️But the ability of the U.S. to lead this effort is now in jeopardy.
The federal government has long been the dominant source of funding for cancer research in the U.S.
Miriam Merad, a cancer immunologist at the Icahn School of Medicine at Mount Sinai in New York City, says that
in a typical year, funding from the NIH accounts for more than half of the research budget at her institution.In President Donald Trump’s first term, threatened cuts to the NIH never quite materialized.
Society is not going to let that happen,
Merad thought.🆘 But just weeks into Trump’s second term, the NIH announced plans to limit indirect contributions to research grants to 15 percent,
-- meaning that for every $100 in funding awarded, only $15 extra would be included for overhead
—a dramatic departure from historical rates in the range of 50 to 60 percent.“This is an operation,” Merad says,
gesturing to the building where she works,
which is dotted with six-figure pieces of equipment
and has an entire floor dedicated to rearing mice used in research.“We have to pay salaries;
we have to buy food for the animals.
We have to pay service contracts because we have instruments that need to be serviced all the time.”These are not expenses that can be easily paused or restarted
based on the fate of a single grant.Within just a few months of the NIH announcement,
Merad’s department had reduced hires of new postdocs,
and Mount Sinai’s medical school had to shrink the size of its incoming class.#neoantigens #driver #antigens #passenger #mutations #neoantigens #checkpointinhibitors #WilliamColey #immunotherapy #stroma #MHC
-
At both Moderna and BioNTech, the complex logistics of conducting the dozens of different quality-control tests required for each production run falls to algorithms powered by AI.
Before being approved for release, doses of SpikeVax underwent 40 distinct tests that tracked the chemistry, biochemistry, microbiology and sterility of every vial.
With COVID vaccines, the sterility test alone,
which ensures that vials are not contaminated with organisms,
took two weeks.Refinements have since compressed that test to eight days, Nickerson says.
Ultimately the goal is to shrink it to five days and complete the other tests within that same window.
“The reason it’s hard is we have to design the equipment,”
he explains.“None of this stuff’s off-the-shelf.”
At the same time, the background science is,
at least in theory,
easily adapted from work that’s already been done.Lennard Lee,
an adviser to the U.K.’s National Health Service overseeing the rollout of clinical trials for cancer vaccines,
says the pandemic gave regulators there a running start on trials for mRNA cancer vaccines.In partnership with BioNTech, the NHS launched a program that aims to provide personalized vaccines to up to 10,000 cancer patients in the next five years.
And the NHS and Moderna have invested in a facility that could produce up to 250 million vaccines per year.
In that interval,
as manufacturers work to reduce production times and costs,
clinical trials will evaluate alternative dosage and delivery mechanisms, Lee says.Although current protocol is for vaccines to target #micrometastases
—small groups of cancer cells that spread to other parts of the body
and linger after cancerous tumors are removed surgically
—there’s no shortage of adjustments that might follow from more data
or improved screening.Could one deliver a therapeutic vaccine to tackle a tumor before it is large enough to operate on?
Or maybe one could even administer a prophylactic shot that prevents tumor formation in the first place?
With a unified health system and world-class research and manufacturing facilities, Lee says,
the U.K. is well positioned to advance research that would answer such questions.Fully realizing the potential of personalized mRNA vaccines for cancer, however,
will require more trials in the U.S.,
which has many more cancer research centers than the U.K.⚠️But the ability of the U.S. to lead this effort is now in jeopardy.
The federal government has long been the dominant source of funding for cancer research in the U.S.
Miriam Merad, a cancer immunologist at the Icahn School of Medicine at Mount Sinai in New York City, says that
in a typical year, funding from the NIH accounts for more than half of the research budget at her institution.In President Donald Trump’s first term, threatened cuts to the NIH never quite materialized.
Society is not going to let that happen,
Merad thought.🆘 But just weeks into Trump’s second term, the NIH announced plans to limit indirect contributions to research grants to 15 percent,
-- meaning that for every $100 in funding awarded, only $15 extra would be included for overhead
—a dramatic departure from historical rates in the range of 50 to 60 percent.“This is an operation,” Merad says,
gesturing to the building where she works,
which is dotted with six-figure pieces of equipment
and has an entire floor dedicated to rearing mice used in research.“We have to pay salaries;
we have to buy food for the animals.
We have to pay service contracts because we have instruments that need to be serviced all the time.”These are not expenses that can be easily paused or restarted
based on the fate of a single grant.Within just a few months of the NIH announcement,
Merad’s department had reduced hires of new postdocs,
and Mount Sinai’s medical school had to shrink the size of its incoming class.#neoantigens #driver #antigens #passenger #mutations #neoantigens #checkpointinhibitors #WilliamColey #immunotherapy #stroma #MHC
-
DMM'den 'BioNTech aşısı gelmedi' iddialarına yalanlama: DMM'den yapılan açıklamada, bazı sosyal medya mecralarında yer alan, "Covid-19 salgını sürecinde BioNTech aşısı gelmediği" yönündeki iddiaların gerçeği yansıtmadığı ve kamuoyunu yanıltmaya yönelik dezenformasyon içerdiği belirtildi.
Covid-19'a karşı geliştirilen BioNTech mRNA aşılarının, klinik kullanım amacıyla doğrudan BioNTech SE firmasından… https://www.eshahaber.com.tr/haber/dmm-den-biontech-asisi-gelmedi-iddialarina-yalanlama-279996.html?utm_source=dlvr.it&utm_medium=mastodon EshaHaber.com.tr #BioNTech #Covid19 #aşı #sağlık #dezenformasyon
-
Impfmöglichkeit Booster Auffrischung 💉 #Biontech #Comirnaty #L.P.8.1 📆 mit Termin (📞), nächstmalig 18.12.25, 9:30-11:30 Uhr 🏥 Condor Apotheke 📍 Neuköllner Str. 348-350 12355 #Berlin #Rudow #Neukölln 📞 030-6631047 📧 [email protected] #COVID19 #CovidIsNotOver #TeamVorsicht #Impfung #impflp81
-
Impfmöglichkeit Booster Auffrischung 💉Grippe #Biontech #Comirnaty #L.P.8.1 📆 online Termine ab 15.12. (Covid) bzw. 22.12. (Grippe) 🏥 #Marienburg Apotheke 📍 Pferdmengesstr. 22 50968 #Köln #NRW 📞0221-383433 📧 [email protected] #COVID19 #CovidIsNotOver #TeamVorsicht #Impfung #impflp81
-
Impfmöglichkeit Booster Auffrischung 💉Grippe #Biontech #Comirnaty #L.P.8.1 📆 Fr-Nachmittag ohne od. mit Termin (online) 📍Märkische Apotheke Am Försterweg 93 15344 #Strausberg #Märkisch-Oderland #Brandenburg 📞 03341-44276 📧 [email protected] #COVID19 #CovidIsNotOver #TeamVorsicht #Impfung #impflp81
-
Impfmöglichkeit Booster Auffrischung 💉Grippe #Biontech #Comirnaty #L.P.8.1 📆 mit Termin (📞,📧) 🏥 Arzt-Praxis am Lausitzer Platz 📍Audre-Lorde-Str. 37 10997 #Berlin #Kreuzberg #Kreuzberg36 #SO36 📞 030-6123214 📧 [email protected] #COVID19 #CovidIsNotOver #TeamVorsicht #Impfung #impflp81
RE: https://bsky.app/profile/did:plc:2smxrr5cuqgabfhqpntr7gdv/post/3m4ddqp3ek22b -
Impfmöglichkeit Booster Auffrischung 💉Grippe #Biontech #Comirnaty #L.P.8.1 📆15.11.25 9-11:30 U. ohne Termin 🏥Praxiszentrum Friedrichstraße 📍Friedrichstr. 52 77955 #Ettenheim #Ortenaukreis #BaWü 📞07822-7898790 📧 [email protected] #COVID19 #CovidIsNotOver #TeamVorsicht #Impfung #impflp81
-
Impfmöglichkeit Booster Auffrischung 💉Grippe #Biontech #Comirnaty #L.P.8.1 📆Termin (📞) 🏥gesundleben Apotheke Christian Willeke e.K. 📍Hauptstr. 111 59846 #Sundern #Hochsauerlandkreis #NRW 📞02933-97300 📧 [email protected] #COVID19 #CovidIsNotOver #TeamVorsicht #Impfung #impflp81
-
Impfmöglichkeit Booster Auffrischung 💉Grippe #Biontech #Comirnaty #L.P.8.1 📆 online Termine ab 24.11.25 🏥 Adler-Apotheke 📍 Schmiedestr. 37 24376 #Kappeln #Schleswig-Flensburg #Schleswig-Holstein #SH 📞04642-1064 📧 [email protected] #COVID19 #CovidIsNotOver #TeamVorsicht #Impfung #impflp81
-
Impfmöglichkeit Booster Auffrischung 💉 #Biontech #Comirnaty #L.P.8.1 Grippe 📆 mit Termin (online, ab 27.10.25) 🏥 Bahnhof-Apotheke 📍 Bahnhofsplatz 7 69412 #Eberbach #Rhein-Neckar-Kreis #BaWü 📞 06271-5456 📧 [email protected] #COVID19 #CovidIsNotOver #TeamVorsicht #Impfung #impflp81
-
Impfmöglichkeit Booster Auffrischung 💉Grippe Biontech Comirnaty #L.P.8.1 📆 Termine ab 11/25 per 📞 🏥 Gesundheitsamt 📍Neustädter Str. 13 16816 #Neuruppin Lkr. #Ostprignitz-Ruppin #Brandenburg 📞 03391-6885308 📧 [email protected] #COVID19 #CovidIsNotOver #TeamVorsicht #Impfung #impflp81
-
Impfmöglichkeit Booster Auffrischung 💉Grippe Biontech Comirnaty #L.P.8.1 📆 Termine ab 11/25 per 📞 🏥 Gesundheitsamt 📍Neustädter Str. 13 16816 #Neuruppin Lkr. #Ostprignitz-Ruppin #Brandenburg 📞 03391-6885308 📧 [email protected] #COVID19 #CovidIsNotOver #TeamVorsicht #Impfung #impflp81
-
Impfmöglichkeit Booster Auffrischung 💉Grippe Biontech Comirnaty #L.P.8.1 📆 Termine ab 11/25 per 📞 🏥 Gesundheitsamt 📍Neustädter Str. 13 16816 #Neuruppin Lkr. #Ostprignitz-Ruppin #Brandenburg 📞 03391-6885308 📧 [email protected] #COVID19 #CovidIsNotOver #TeamVorsicht #Impfung #impflp81
-
Impfmöglichkeit Booster Auffrischung 💉Grippe Biontech Comirnaty #L.P.8.1 📆 mit Termin (📞/online) 🏥 Gesundheitsamt 📍 #Erzgebirgskreis #Sachsen #Annaberg-Buchholz #Aue Bad Schlema #BadSchlema #Marienberg 🚦Mindestalter & Stikotreue unklar ⬇️ #COVID19 #CovidIsNotOver #TeamVorsicht #Impfung #impflp81
